Therapeutics Company Announces Positive Findings From Oxylanthanum Carbonate Clinical Trial

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company committed to developing therapies for patients with kidney disease, recently announced promising initial results from a patient-reported outcome survey conducted during their pivotal clinical trial UNI-OLC-201. This study evaluated oxylanthanum carbonate (OLC) in patients with hyperphosphatemia who have chronic kidney disease and are on dialysis. The top-line results were reported on June 25, 2024, and indicated patient satisfaction and preference for OLC over existing phosphate binders. $Unicycive Therapeutics(UNCY.US)$